Skip to content
← Full study record

NCT01969838 · MORE INFO

Limitations, agreements, and source contact

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis · Source last updated 2023-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Agreements varied with individual investigators, but did not prohibit any investigator from publishing. Investigators were not to publish results of the study until a period of time (eg. 2 years) following completion of the trial at all participating institutions but could do so earlier with consent of the Sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
GSKClinicalSupportHD@gsk.com
organization
Sierra Oncology, a GlaxoSmithKline company
phone
866-435-7343
title
GSK Response Center
Complete source fields
certain Agreement
other Details
Agreements varied with individual investigators, but did not prohibit any investigator from publishing. Investigators were not to publish results of the study until a period of time (eg. 2 years) following completion of the trial at all participating institutions but could do so earlier with consent of the Sponsor.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
GSKClinicalSupportHD@gsk.com
organization
Sierra Oncology, a GlaxoSmithKline company
phone
866-435-7343
title
GSK Response Center

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice